One04 Therapeutics to present late-breaking interim Phase 1 results for CPV-104 in C3 glomerulopathy at ASN Kidney Week followed by Virtual KOL Event

Phase 1CPV-104Positive

AI Analysis

Summary

One04 Therapeutics will present late-breaking interim Phase 1 results for CPV-104 in C3 glomerulopathy at ASN Kidney Week, followed by a Virtual KOL Event.

Clinical Trial Data

Phase

Outcome Details

Late-breaking interim Phase 1 results presentation

Importance:5/10

Sentiment:

0.40

Phase 1CPV-104C3 glomerulopathyASN Kidney Weeklate-breakingclinical trial

Read the original article

Published by GlobeNewswire Clinical Studies on October 6, 2026 6:30 AM

Read Original